Drug Interaction Study Of Apixaban With Cyclosporine Or Tacrolimus: Results From A Phase 1, Randomized, Open-Label, Crossover Study In Healthy Volunteers

BACKGROUND Solid organ transplant recipients commonly require anticoagulation. Apixaban (APX) is principally metabolized by CYP3A4, undergoes direct intestinal excretion, and is a substrate to P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) transporters. We examined the potential drug interaction between cyclosporine (CsA) and tacrolimus (Tac) [combined inhibitors of CYP3A4, P-gp and, BCRP] with APX.https://jdc.jefferson.edu/petposters/1005/thumbnail.jp

17th Annual Pancreatic Cancer and Related Diseases Patient Symposium

On November 12, 2022, Charles J. Yeo, MD, FACS, and the multidisciplinary team of clinicians and scientists hosted the 17th Annual Pancreatic Cancer & Related Diseases Symposium. View our Pancreatic Cancer Program 2022 Update to learn more about Dr. Yeo and the team’s great work! PROGRAM Welcome and Program OverviewCharles J. Yeo, MD, FACSSamuel D. Gross Professor and Chair of Surgery SKCC Director’s Overview Andrew Chapman, DO, FACPExecutive Vice President of Oncology Services, Enterprise Director and Chief of the Sidney Kimmel Cancer Center, Professor of Medical Oncology and Co-Director, Jefferson Senior Adult Oncology Center The Jefferson Pancreas Tumor Registry: 2021-2022 Annual Update and Long-term Complications Reported by Registrants Theresa P. Yeo, PhD, MPH, AOCNP, ACNP-BC, FAANPProfessor and Co-Director, Jefferson Pancreas Tumor Registry Angiotensin Blockage in Pancreatic Cancer: A Population StudyHarish Lavu, MD, FACS Professor of Surgery and Section Chief of Hepatopancreatobiliary Surgery and Co-Director, Jefferson Pancreas Tumor Registry Stress Granules Answer a Pancreatic Cancer Mystery Elda Grabocka, PhD Assistant Professor of Research, Departments of Pharmacology, Physiology and Cancer Biology & Surgery Therapeutic Landscape in Management of Pancreatic Ductal Adenocarcinoma (PDAC) – Medical Oncology Perspective Babar Bashir, MD, MS, FACP Assistant Professor of Medical Oncology JMP PaC: Molecular Profiling of Pancreatic Cancer at SKCC and Beyond Jennifer Johnson, MD, PhDAssociate Professor of Medical Oncology and Co-Director, SKCC Precision Medicine Initiative Christopher McNair, PhD Assistant Professor of Medical Oncology and Co-Director, SKCC Precision Medicine Initiative Hien Dang, PhDAssistant Professor and Vice Chair of Research, Department of Surgery Survivor TestimonialDonna Adelsberg Survivor Tribute Phot

Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic.

BACKGROUND: Surgical services are preparing to scale up in areas affected by COVID-19. This study aimed to evaluate the association between preoperative SARS-CoV-2 testing and postoperative pulmonary complications in patients undergoing elective cancer surgery. METHODS: This international cohort study included adult patients undergoing elective surgery for cancer in areas affected by SARS-CoV-2 up to 19 April 2020. Patients suspected of SARS-CoV-2 infection before operation were excluded. The primary outcome measure was postoperative pulmonary complications at 30 days after surgery. Preoperative testing strategies were adjusted for confounding using mixed-effects models. RESULTS: Of 8784 patients (432 hospitals, 53 countries), 2303 patients (26.2 per cent) underwent preoperative testing: 1458 (16.6 per cent) had a swab test, 521 (5.9 per cent) CT only, and 324 (3.7 per cent) swab and CT. Pulmonary complications occurred in 3.9 per cent, whereas SARS-CoV-2 infection was confirmed in 2.6 per cent. After risk adjustment, having at least one negative preoperative nasopharyngeal swab test (adjusted odds ratio 0.68, 95 per cent confidence interval 0.68 to 0.98; P = 0.040) was associated with a lower rate of pulmonary complications. Swab testing was beneficial before major surgery and in areas with a high 14-day SARS-CoV-2 case notification rate, but not before minor surgery or in low-risk areas. To prevent one pulmonary complication, the number needed to swab test before major or minor surgery was 18 and 48 respectively in high-risk areas, and 73 and 387 in low-risk areas. CONCLUSION: Preoperative nasopharyngeal swab testing was beneficial before major surgery and in high SARS-CoV-2 risk areas. There was no proven benefit of swab testing before minor surgery in low-risk areas